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Abstract: Streptozotocin (STZ) is an antibiotic often used in the treatment of different 
types of cancers. It is also highly cytotoxic to the pancreatic beta-cells and therefore is 
commonly used to  induce  experimental type 1  diabetes in  rodents.  Resistance towards 
STZ-induced cytotoxicity in cancer cells has also been reported. Our previous studies have 
reported  organ-specific  toxicity  and  metabolic  alterations  in  STZ-induced  diabetic  rats. 
STZ  induces  oxidative  stress  and  metabolic  complications.  The  precise  molecular 
mechanism  of  STZ-induced  toxicity  in  different  tissues  and  carcinomas  is,  however, 
unclear. We have, therefore, investigated the mechanism of cytotoxicity of STZ in HepG2 
hepatoma cells in culture. Cells were treated with different doses of STZ for various time 
intervals and the cytotoxicity was studied by observing the alterations in oxidative stress, 
mitochondrial redox and metabolic functions. STZ induced ROS and RNS formation and 
oxidative stress as measured by an increase in the lipid peroxidation as well as alterations 
in the GSH-dependent antioxidant metabolism. The mitochondria appear to be a highly 
sensitive  target  for  STZ  toxicity.  The  mitochondrial  membrane  potential  and  enzyme 
activities were altered in STZ treated cells resulting in the inhibition of ATP synthesis. 
ROS-sensitive  mitochondrial  aconitase  activity  was  markedly  inhibited  suggesting 
increased oxidative stress in STZ-induced mitochondrial toxicity. These results suggest 
that STZ-induced cytotoxicity in HepG2 cells is mediated, at least in part, by the increase 
in ROS/RNS production, oxidative stress and mitochondrial dysfunction. Our study may be 
significant for better understanding the mechanisms of STZ action in chemotherapy and 
drug induced toxicity. 
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1. Introduction 
Streptozotocin (STZ) is an antibiotic often used in the treatment of different types of cancers [1,2]. 
Structurally,  it  is  an  N-nitrosourea  derivative  of  D-glucosamine  that  was  first  isolated  from 
Streptomyces achromogenes [3]. It is a broad spectrum antibiotic and alkylating genotoxic agent which 
possesses antibacterial, tumoricidal, carcinogenic and diabetogenic properties [4–6]. However, STZ is 
not a drug of choice for treatment of cancers due to development of resistance to its genotoxic effects [7]. 
Moreover, severe toxicities were observed in different cancer patients when STZ was used alone or in 
combination with other antineoplastic drugs [8]. More specifically, STZ exhibits pancreatic beta-cell 
toxicity and is often used to induce diabetes in experimental animals [9–10]. Beta-cell toxicity and 
diabetogenic properties of STZ are mediated through diverse mechanisms including targeted uptake of 
STZ in beta cells by Glut2 receptors [11] and increased oxidative stress due to NO release and ROS 
production [12–16]. The exact mechanism of targeted beta-cell toxicity is, however, not clear. STZ 
induces beta-cell dysfunction and apoptosis at lower doses while causing beta-cell necrosis at higher 
doses. Insulin-secretory cells also develop resistance on repeated exposures to STZ through a wide 
spectrum of toxin tolerance mechanisms [17]. Betacyte, a genetically engineered insulin-secreting liver 
cell line derived from HepG2 cancer cells, known to exhibit general resistance to STZ, offers hope to 
elucidate the mechanism of action of beta-cell toxins in autoimmune destruction of the pancreas and in 
reversal of type 1 diabetes [18]. This study has also reported that the metabolic and morphological 
changes due to STZ treatment were similar in betacyte and HepG2 cells. In the present study, we have 
investigated dose- and time-dependent effects of STZ on HepG2 cell survival, mitochondrial function 
and oxidative stress related metabolic alterations. Our results have demonstrated that STZ  induces 
cytotoxicity  in  HepG2  cells  through  increased  oxidative  stress  and  mitochondrial  respiratory 
dysfunction with a limited induction of intrinsic mitochondrial apoptosis pathways. 
2. Results and Discussion 
2.1. Effect of STZ on HepG2 Cell Viability  
A  decrease in  mitochondrial dehydrogenase based cell survival  was  observed  only  with  higher 
concentrations of STZ (Figure 1). At low concentrations (1–5 mM) of STZ, no significant alteration in 
cell viability (5–10% changes) was observed over 24 h. Ten millimole per liter STZ treatment for 24 h 
or 48 h caused about 40% inhibition in cell viability. The maximum inhibition (~80%) was, however, 
observed in cells treated with 20 mM STZ for 48 h. 
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Figure 1. Cell viability assay by MTT. HepG2 cells (~5  10
4) were grown in 96-well 
plates for 24 h and treated with different concentrations (0–20 mM) of STZ for different 
time  intervals.  The  formazan  crystals  formed,  following  the  reduction  of  MTT  by 
metabolically  active  (viable)  cells,  were  solubilized  in  acidified  isopropanol  and 
quantitated  using  the  ELISA  reader  at  570  nm.  Values  are  mean  ±   S.E.M.  for  three 
individual experiments. Asterisks indicate significant difference (P ≤ 0.05) relative to the 
untreated control cells. 
 
2.2. Effect of STZ on ROS, NO Production and LPO 
STZ causes a dose- and time-dependent increase in ROS production in HepG2 cells, which were 
observed microscopically and measured fluorimetrically (Figure 2). Increased ROS production in live 
HepG2 cells were captured microscopically using two different probes, CM-H2XROS and DCFDA, 
which again showed maximum fluorescence with 10 mM STZ at 48 h.  
A time-dependent  increase in  ROS  production was  also  measured  fluorimetrically  as  shown in 
Figure 3a. Significant increases in ROS production were observed, with a marked increase (4-fold) 
observed with 10 mM STZ at 48 h. Figure 3b shows a time- and dose-dependent increase in NO 
production in STZ treated HepG2 cells. NO production was not significantly increased with 1 mM or 
10 mM STZ after 24 h. On the other hand, 48 h treatments resulted in a marked increase (~70%) in NO 
production. A dose- and time-dependent increase in NADPH-dependent membrane bound LPO was 
also  observed  in  HepG2  cells  after  STZ  treatment  (Figure  3c).  These  results  clearly  suggest  that 
increased oxidative stress in STZ treated HepG2 cells is due to increased ROS/NO production.  
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Figure 2. STZ-induced ROS production. HepG2 cells (1 ×  10
5) seeded in cover slip loaded 
6-well plates were treated with medium containing 0.5 µM freshly prepared CM-H2XROS 
and incubated for 15 min at room temperature. After washing twice with PBS (pH 7.4) 
cells were fixed with 3.7% formaldehyde and visualized using an Olympus fluorescence 
microscope (a); Typical representations from untreated control and 10 mM STZ treated 
slides, from three individual experiments are shown. Intracellular production of reactive 
oxygen species was also measured in control untreated and STZ treated HepG2 cells using 
the cell permeable probe, DCFDA. Cells (~1 ×  10
5 cells/mL) were grown on cover slips 
and incubated with 5 µM DCFDA for 30 min at 37 ° C. Cells were washed twice with PBS, 
and fluorescence was immediately analyzed microscopically as described above. Typical 
results from untreated control and 10mM STZ treated cells from three experiments are 
shown (b). 
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Figure 3. STZ-induced ROS, NO and LPO. Intracellular production of reactive oxygen 
species was measured fluorimetrically in control untreated and STZ treated HepG2 cells 
using DCFDA (a); For NO assay, HepG2 cells (2 ×  10
5 cells/well) were cultured in 6-well 
plates for 24 h prior to STZ treatments. NO production was determined by measuring the 
concentration of total nitrite in the culture supernatants (b) with Griess reagent (R & D 
Systems  Inc.);  NADPH-dependent-membrane  LPO  in  the  mitochondria  of  STZ  treated 
HepG2  cells  was  measured  as  thiobarbituric  acid  reactive  substances  (TBARS)  using 
malonedialdehyde  as  a  standard  (c).  Results  are  expressed  as  mean  ±   S.E.M.  of  three 
independent  experiments.  Asterisks  indicate  significant  difference  (P  ≤  0.05)  from 
untreated cells. 
 
 
2.3. Effects of STZ on Mitochondrial GSH Concentration and GSH Metabolism  
A dose-and time-dependent decrease in mitochondrial GSH was observed in HepG2 cells after STZ 
treatment (Figure 4a). More than a 2-fold decrease in mitochondrial GSH concentration was observed 
after 48 h of treatment with 10 mM STZ. Treatment with 1 mM STZ for 24 h showed little effect on 
the mitochondrial GSH pool. Similarly, a dose- and time-dependent inhibition of GSH conjugating 
enzyme, GST was observed after STZ treatment. 1 mM and 10 mM STZ treatments for 48 h resulted 
in  a  marked  decrease  (~4-fold)  in  GSH-conjugation  of  CDNB  by  GST  enzymes  (Figure  4b).  
As shown in Figure 4c, there was no significant alteration in mitochondrial GSH-Px activity after STZ 
treatment.  On  the  other  hand,  a  significant  decrease  in  GSH-reductase  activity  was  observed  
(Figure 4d). These results indicate that the reduced GSH pool in the mitochondria might be due to a Int. J. Mol. Sci. 2012, 13  5756 
 
decrease in regeneration of oxidized glutathione in the mitochondria or due to inhibition of cytosolic 
GSH transport to mitochondria in STZ treated HepG2 cells. 
Figure  4.  STZ-induced alterations in GSH metabolism. HepG2 cells were treated with 
different doses of STZ for different time intervals as given in the Materials and Methods. 
Mitochondrial GSH concentration (a); glutathione S-transferase (GST) (b); GSH-Px (c) and 
GSH-reductase  (d)  were  measured.  Results  are  expressed  as  mean  ±   S.E.M.  of  three 
independent  experiments.  Asterisks  indicate  significant  difference  (P  ≤  0.05)  from 
untreated cells. 
 
 
2.4. Effects of STZ on Mitochondrial Respiratory Function and ATP Production  
Alterations  in  mitochondrial respiratory enzymes  and bioenergetics  have also  been observed in 
HepG2 cells after STZ treatment (Figure 5). Though significant inhibition in Complex I activity was 
observed after STZ treatment (Figure 5a), the activity of the terminal respiratory enzyme, Complex IV 
(cytochrome c oxidase) was markedly inhibited after 48 h of 10 mM STZ treatment (Figure 5b).  
A dose- and time-dependent inhibition of ROS-sensitive mitochondrial matrix enzyme, aconitase, was 
also  observed  after  STZ  treatment  (Figure  5c).  Similarly,  ATP  levels  also  decreased  after  STZ 
treatment (Figure 5d). 
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Figure  5.  STZ-induced  alterations  in  mitochondrial  enzyme  activity.  Freshly  isolated 
mitochondria from  untreated  control  and STZ  treated  HepG2 cells  were used to assay 
mitochondrial respiratory chain enzymes (a: Complex I, b: Complex IV) and the matrix 
enzyme (c: aconitase) activities as described in the Materials and Methods. ATP content (d) 
was measured in the total cell lysate using the ATP Bioluminescent somatic cell assay kit 
as described in the Materials and Methods. The values are expressed as mean ±  S.E.M. of 
three independent experiments. Asterisks indicate significant difference (P ≤ 0.05) from 
untreated cells.  
 
 
2.5. Effects of STZ on Cell Survival and Apoptosis  
STZ treatment resulted in induction of apoptosis in HepG2 cells as observed by a decrease in 
mitochondrial  membrane  potential  (Figure  6a)  and  increased  nuclear  condensation  (Figure  6b).  
An increase in apoptosis was also observed by an increased activity of terminal apoptotic enzyme  
caspase-3 (Figure 6c). This increased apoptosis after STZ treatment was apparently due to inhibition of 
expression of the antiapoptotic protein, Bcl-2 (Figure 6d). 
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Figure 6. STZ-induced apoptosis and mitochondrial permeability transition. HepG2 cells 
were  treated  with  different  concentrations  of  STZ  for  different  time  intervals  and 
membrane  permeability  transition  (a)  was  measured  using  a  cationic  fluorescent  dye 
(DePsipher™, R & D System Inc.) according to the vendor’s protocol. DePsipher has the 
property of aggregating upon membrane polarization forming an orange-red fluorescent 
(absorption/emission  585/590  nm)  compound.  If  the  membrane  potential  is  reduced,  
the  dye  cannot  access  the  transmembrane  space  and  remains  in  its  green  fluorescent 
(510/527 nm) monomeric form. Results show a typical representation of three individual 
experiments, from untreated control and 10 mM STZ treated cells. Apoptosis measurement 
was performed by using Hoechst33342 dye staining of fragmented nuclei (b). Cover slips 
with adherent cells were treated with STZ, fixed with 3.7% formaldehyde and stained with 
Hoechst33342 (10 µg/mL) for 20 min at RT. The cover slips were washed, mounted on 
glass  slides  and  analyzed  by  fluorescence  microscopy.  Cells  with  signs  of  apoptosis 
showed fragmented nuclei. Typical results from three experiments from untreated control 
and 10 mM STZ treated cells are presented. Caspase-3 activity in HepG2 cells treated with 
STZ  was  measured  colorimetrically  using  the  substrate  DEVD  peptide  conjugated  to  
p-nitroanaline  as  described  in  the  vendor’s  protocol  (c).  The  values  are  expressed  as  
mean ±  S.E.M. of three independent experiments. Asterisks indicate significant difference 
(P  <  0.05)  from  untreated  cells.  Mitochondrial  extract  (50  µg  protein)  from  control 
untreated and STZ treated cells was separated on 12% SDS-PAGE and immunoblotted 
using  Bcl-2  antibody  (d).  Tom-40  was  used  as  a  loading  control.  R.I.  values  indicate 
relative intensity of the protein band using expression of protein in control untreated cells 
as  1.0.  The  figure  is  representative  of  2–3  experiments.  Molecular  weight  (kDa)  is 
indicated by an arrow. 
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Figure 6. Cont. 
 
 
 
2.6. Effect of STZ on the Expression of Apoptotic Protein Markers  
Figure 7 shows an increased expression of iNOS and increased translocation of NF-κBp65 from the 
cytosol to the nucleus after STZ treatment. These results are in agreement with the observation of 
increased  oxidative  and  nitrosative  stress  after  STZ  treatment  and  that  these  changes  might  have 
altered the NF-κB-dependent cell signaling in HepG2 cells. 
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Figure 7. Expression of apoptotic markers. Cytosolic and nuclear extract (50 µg protein) 
from control untreated and STZ-treated HepG2 cells were separated on 12% SDS-PAGE 
and transferred on to nitrocellulose paper by Western blotting as described in the Materials 
and Methods. Specific antibodies against iNOS and NF-κBp65 were used to identify the 
expression of these proteins. Beta-actin was used as a loading control. R.I. values indicate 
relative intensity (of the protein band) using expression of proteins in control untreated 
cells as 1.0. The figures are representative of 2–3 experiments. Molecular weights (kDa) 
are indicated by arrows. 
 
2.7. Discussion 
STZ is a diabetogenic DNA alkylating agent that is commonly used in experimental models of type 
1 diabetes in rodents [5,6]. Even therapeutic doses (up to 15 mM) of STZ induce pancreatic beta-cell 
death by inducing apoptosis followed by necrosis at higher doses (up to 30 mM) [19]. However, STZ 
treatment  (up  to  20  mM)  has  been  reported  to  cause  only  apoptotic  cell  death  in  other  cellular  
systems [20]. It has been reported that the increased STZ toxicity towards beta cells depends on the 
expression of GLUT2 receptors which preferentially facilitate the uptake of STZ [11]. Several in vitro 
studies using insulin secreting insulinoma cells, keratinocytes and genetically engineered hepatocytes 
have also shown that STZ (up to 20 mM) causes oxidative stress and apoptosis [11,18,20]. The precise 
molecular  mechanism  and  metabolic  targets  of  STZ  toxicity  in  hepatocytes  are  not  known.  The 
mechanism of antineoplastic action of STZ in human hepatoma is also not clearly understood. We, 
therefore, have investigated the dose- and time-dependent effects of STZ on human hepatoma HepG2 
cells,  in  culture.  Using  the  mitochondrial  dehydrogenase  based  cellular  viability  MTT  assay,  our 
results have shown that STZ induces significant cell death only after 48 h of treatment with 20 mM of 
the drug. Our results have also shown that 10 mM STZ resulted in about 40% cell death. At this dose, 
HepG2 cells  exhibit  increased ROS  and NO production and  an increase in  LPO. The increase  in Int. J. Mol. Sci. 2012, 13  5761 
 
oxidative stress is associated with increased apoptosis of HepG2 cells as evidenced by an increase in 
caspase-3 activity and reduction in the expression of antiapoptotic protein, Bcl-2, as also the nuclear 
fragmentation observed by Hoechst staining. A recent study has also suggested that the treatment of rat 
insulinoma  cells  (RINm5F)  with  STZ  induces  Bcl-2  dependent  apoptosis  which  is  protected  by 
increasing the expression of this protein [21]. Several studies using in vitro cell culture or in vivo 
animal models, including our own, have suggested that STZ treatment causes an increase in oxidative 
stress and alterations in antioxidant GSH metabolism [12–15,22]. In the present study using HepG2 
cells, we have observed a reduced mitochondrial GSH antioxidant pool due to the reduced recycling of 
oxidized glutathione resulting from the inhibition of mitochondrial GSH-reductase enzyme. We have 
also demonstrated that the increased ROS production and reduced GSH concentration in HepG2cells 
treated with STZ has resulted in compromised mitochondrial bioenergetics. Mitochondrial membrane 
potential  was  reduced  after  STZ  treatment  which  resulted  in  inhibition  of  the  activities  of  the 
respiratory complexes and ROS-sensitive aconitase enzyme followed by a reduction in ATP synthesis. 
Our in vivo studies have also shown increased mitochondrial dysfunction after STZ treatment [14,15]. 
In the present study, we have also provided evidence that the increased oxidative stress, apoptosis and 
mitochondrial dysfunction in HepG2 cells might be associated with altered NF-κB based cell signaling 
as STZ increases the expression of iNOS and translocation of NF-κBp65 (RelA) transcription factor to 
the  nucleus.  STZ  has  been  reported  to  alter  NO/NF-κB  dependent  cell  signaling  [23,24].  STZ 
methylates DNA both under in vitro and in vivo conditions and this methylated DNA may have altered 
regulation of DNA transcription in drug treated cells [25,26]. 
3. Experimental Section 
3.1. Materials 
Streptozotocin  (STZ),  cytochrome  c,  reduced  and  oxidized  glutathione  (GSH),  
5,5'-dithio-bis(2-nitrobenzoic  acid),  1-chloro  2,4-dinitrobenzene  (CDNB),  cumene  hydroperoxide, 
glutathione  reductase,  thiobarbituric  acid,  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), NADH, NADPH, coenzyme Q2, antimycin A, dodecyl maltoside, Hoechst 33342 and 
ATP bioluminescent somatic cell assay kits were purchased from Sigma-Aldrich Fine Chemicals 
(St Louis, MO, USA). 2',7'-Dichlorofluorescein diacetate (DCFDA) and CM-H2XROS were procured 
from Molecular Probes (Eugene, OR, USA). Aconitase assay kit was purchased from Oxis International 
Inc.  (Portland,  OR,  USA).  Kits  for  mitochondrial  membrane  potential,  nitric  oxide  and  caspase-3 
assays were purchased from R & D System, MN, USA. HepG2 cells were obtained from American 
Type Culture Collection (Manassas, VA, USA). Polyclonal antibodies against beta-actin, Tom-40,  
NF-κB, iNOS and Bcl-2 were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 
Reagents for cell culture, SDS-PAGE and Western blot analyses were purchased from Gibco BRL 
(Grand Island, NY, USA) and Bio Rad Laboratories (Richmond, CA, USA).  
3.2. HepG2 Cell Culture and STZ Treatment 
HepG2 cells were grown in poly-L-lysine coated 75 cm
2 flasks (~2.0–2.5 ×  10
6 cells/mL) in DMEM 
medium supplemented with 1% nonessential amino acids, 2 mM glutamine, 10% heat inactivated fetal Int. J. Mol. Sci. 2012, 13  5762 
 
bovine serum in a humidified incubator in the presence of 5% CO2–95% air at 37 ° C. HepG2 cells 
were  treated  with  0–20  mM  STZ  (dissolved  in  citrate  buffer,  pH  4.4  and  diluted  in  DMEM  to 
appropriate concentrations just before use) for different time intervals (24 to 48 h). Control cells were 
treated with vehicle alone. Concentrations and time points for STZ treatment in this study were based 
on MTT cytotoxicity tests and on published reports on in vitro and in vivo use of STZ [18,19].After the 
desired  time  of  treatment,  cells  were  harvested,  washed  with  PBS  (pH  7.4)  and  homogenized  in  
H-medium buffer (70 mM sucrose, 220 mM mannitol, 2.5 mM HEPES, 2 mM EDTA, and 0.1 mM 
phenylmethylsulfonylfluoride,  pH  7.4)  at  4  °C   Cellular  fractionation  to  prepare  mitochondria  and 
postmitochondrial (PMS) fractions were performed by centrifugation and the purity of the isolated 
fractions for cross contaminations was checked as described before [27].  
3.3. MTT Cell Viability Test  
The effect of different concentrations of STZ on cell viability test was evaluated based on the 
metabolic  activity  of  mitochondrial  dehydrogenases,  which  cleave  the  dye  MTT  to  form  purple 
formazan crystals as described previously [27]. 
3.4. Measurement of ROS, NO and LPO  
To evaluate direct production of mitochondrial ROS in HepG2 cells, ROS-specific staining with 
Mito  Tracker  Red  (CM-H2XROS)  was  used.  Respiring  cells  which  produce  ROS  (mainly  H2O2) 
convert (oxidize) the dye to a cationic form, which interacts with mitochondrial proteins and generates 
red fluorescence. Briefly, HepG2 cells (1 ×  10
5) were seeded in cover slip loaded 6-well plates. After 
treatment with appropriate doses of STZ for appropriate time intervals, the cells were then treated with 
medium  containing  0.5  µM  freshly  prepared  CM-H2XROS  and  incubated  for  15  min  at  room 
temperature. After washing twice with PBS (pH 7.4), cells were fixed with 3.7% formaldehyde and 
mounted on to microscope slides and visualized using the Olympus fluorescence microscope. A typical 
result showing red stained cells has been shown. 
Intracellular production of reactive oxygen species was also measured using the cell permeable 
probe,  DCFDA,  which  preferentially  measures  peroxides.  Briefly,  STZ  treated  and  control  cells  
(~1 ×  10
5 cells/mL) were grown on cover slips and incubated with 5 µM DCFDA for 30 min at 37 ° C. 
Cells were washed twice with PBS, and fluorescence was immediately analyzed microscopically as 
described above.  DCFDA based ROS  assay  was  also  performed and  measured  fluorimetrically  as 
described before [15]. 
For NO assay, HepG2 cells (2 ×  10
5 cells/well) were cultured in 6-well plates for 24 h prior to STZ 
treatments.  NO  production  was  determined  by  measuring  the  concentration  of  total  nitrite  in  the 
culture supernatants using Griess reagent (R & D Systems Inc.). 
NADPH-dependent-membrane  lipid  peroxidation  in  the  mitochondria  of  STZ  treated  and  
control  HepG2  cells  was  measured  as  thiobarbituric  acid  reactive  substances  (TBARS)  using 
malonedialdehyde as standard as described previously [27,28]. 
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3.5. Measurement of GSH Metabolism  
HepG2 cells were treated with different doses of STZ for appropriate time intervals as mentioned 
above. Mitochondrial GSH concentration and activities of GSH-Px, GSH-reductase and glutathione  
S-transferase (GST) were measured in the isolated mitochondria as described before [28].  
3.6. Measurement of Mitochondrial Functions 
3.6.1. Measurement of Mitochondrial Membrane Potential (MMP) 
Loss  of  mitochondrial  membrane  potential  was  measured  in  HepG2  cells  after  treatment  with 
varying  concentrations  of  STZ  at  different  time  intervals  using  a  fluorescent  cationic  dye,  
DePsipher™ (R&D System Inc.) according to the vendor’s protocol. DePsipher has the property of 
aggregating  upon  membrane  polarization  forming  an  orange-red  fluorescent  (absorption/emission 
585/590 nm) compound. If membrane potential is disturbed, the dye cannot access the transmembrane 
space and remains in its green fluorescent (510/527 nm) monomeric form. Briefly, cells were grown 
on coverslips as described above and adherent cells were treated with STZ and then incubated with 
DePsipher reagent in pre-warmed medium for 20 min in a 37 ° C incubator. Cover slips were washed 
with  PBS  and  fixed with  fresh 3.7% formaldehyde. Healthy  cells  containing red  aggregates were 
differentiated from apoptotic cells (containing only green monomers) by fluorescence microscopy.  
A typical result from three experiments is presented. 
3.6.2. Measurement of Mitochondrial Respiratory Functions and ATP Content 
Freshly isolated mitochondria (5 µg protein) from untreated and STZ-treated HepG2 cells were 
suspended in 1.0 mL of 20 mM potassium phosphate buffer, pH 7.4, in the presence of the detergent, 
lauryl maltoside (0.2%). NADH-ubiquinone oxidoreductase (NADH-dehydrogenase (complex I) and 
cytochrome c oxidase (complex IV) were measured using the substrates CoenzymeQ2 and reduced 
cytochrome c, respectively, by the methods of Birch-Machin and Turnbull [29]. 
Mitochondrial aconitase activity was measured by the NADPH coupled conversion of citrate to 
isocitrate in the presence of isocitrate dehydrogenase using the Bioxytech Aconitase-340 assay kit or 
by using the method described by Spear et al. [30]. Aconitase activity was expressed as the rate of 
formation of NADPH determined at 340 nm. 
The ATP content in the STZ-treated and untreated HepG2 cell lysates was determined using an 
ATP  Bioluminescent  cell  assay  kit  according  to  the  manufacturer’s  recommended  protocol  and 
samples were analyzed using the TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA). A standard 
curve with concentrations of ATP ranging from 0–200 nmol/mL was used for the assay [27].  
3.7. Measurement of Apoptosis 
3.7.1. Nuclear Staining with Hoechst 33342  
Apoptosis measurement was performed by Hoechst dye staining of fragmented nuclei. Cover slips 
with adherent cells were treated with STZ and cells were fixed with 3.7% formaldehyde & stained Int. J. Mol. Sci. 2012, 13  5764 
 
with  Hoechst33342  (10  µg/mL)  for  20  min  at  room  temperature.  The  cover  slips  were  washed, 
mounted  on  glass  slides  and  analyzed  by  fluorescence  microscopy.  Cells  with  signs  of  apoptosis 
showed fragmented nuclei. A typical result from three experiments is presented. 
3.7.2. Assay of Caspase-3 Activity  
Apoptosis  was  also  measured  by  measuring  the  activity  of  caspase-3  enzyme.  HepG2  cells  
(2 ×  10
6 cells/well), grown in 6-well plates, were treated with increasing concentrations of STZ as 
described above. Caspase-3 activity was measured in the cell lysate using the caspase-specific peptide 
substrate, DEVD, conjugated to reporter p-nitroanaline molecules. Cleavage of this peptide by caspase 
releases the chromophore which is measured colorimetrically at a wavelength of 405 nm as described 
in the vendor’s protocol (R & D Systems) as published before [27]. 
3.8. SDS-PAGE and Western Blot Analysis 
Proteins (50 µg) were separated on 12% SDS-PAGE [31] and electrophoretically transferred on to 
nitrocellulose paper by Western blotting [32]. The immunoreactive protein bands were visualized after 
interacting with primary antibodies against iNOS, Bcl-2 and NF-κB p65. Immunoreactive bands were 
visualized using the appropriate conjugated secondary antibodies. Densitometric analysis of the protein 
bands was performed using a gel documentation system (Vilber Lourmat, France) and expressed as 
relative intensity (R.I.) compared to the untreated control. 
3.9. Statistical Analysis 
Values  shown  are  expressed  as  mean  ±   S.E.M.  of  three  individual  experiments.  Statistical 
significance of the data was assessed using SPSS software by analysis of variance followed by Dunnett 
analysis. P values ≤ 0.05 were considered statistically significant. 
4. Conclusions 
In summary, our results have shown that STZ induces apoptosis in HepG2 cancer cells which is 
associated with increased oxidative and nitrosative stress and mitochondrial dysfunction. The study 
also  provides  evidence  that  GSH-dependent  antioxidant  metabolism  is  adversely  affected,  causing 
imbalance in NF-κB dependent redox signaling and mitochondrial bioenergetics. These results may be 
significant for understanding the role of STZ as an antineoplastic and/or diabetogenic agent and its 
associated toxicities in different tissues. 
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